[Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial

[Objective] To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. [Background] Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3...

Full description

Saved in:
Bibliographic Details
Main Author: Liu Xiaojun
Format: Article
Language:zho
Published: Editorial Office of Journal of Colorectal & Anal Surgery 2024-02-01
Series:结直肠肛门外科
Subjects:
Online Access:https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=40&cateName=2024%E5%B9%B4%20%E7%AC%AC30%E5%8D%B7%20%E7%AC%AC1%E6%9C%9F
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850272592401793024
author Liu Xiaojun
author_facet Liu Xiaojun
author_sort Liu Xiaojun
collection DOAJ
description [Objective] To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. [Background] Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial. [Methods] A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed. [Results] Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P = 0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P = 0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P = 0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P = 0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95%CI, 0.46-1.26); P = 0.29]. [Conclusions] The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated.
format Article
id doaj-art-bb508afeb609418c8a7da399a7d27eea
institution OA Journals
issn 1674-0491
language zho
publishDate 2024-02-01
publisher Editorial Office of Journal of Colorectal & Anal Surgery
record_format Article
series 结直肠肛门外科
spelling doaj-art-bb508afeb609418c8a7da399a7d27eea2025-08-20T01:51:45ZzhoEditorial Office of Journal of Colorectal & Anal Surgery结直肠肛门外科1674-04912024-02-01301939410.19668/j.cnki.issn1674-0491.2024.01.017[Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trialLiu Xiaojun[Objective] To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. [Background] Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial. [Methods] A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed. [Results] Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P = 0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P = 0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P = 0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P = 0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95%CI, 0.46-1.26); P = 0.29]. [Conclusions] The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated.https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=40&cateName=2024%E5%B9%B4%20%E7%AC%AC30%E5%8D%B7%20%E7%AC%AC1%E6%9C%9Flocally advanced rectal cancerlocoregional failurelocoregional recurrencetotal neoadjuvant treatment
spellingShingle Liu Xiaojun
[Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
结直肠肛门外科
locally advanced rectal cancer
locoregional failure
locoregional recurrence
total neoadjuvant treatment
title [Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
title_full [Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
title_fullStr [Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
title_full_unstemmed [Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
title_short [Comment] Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
title_sort comment locoregional failure during and after short course radiotherapy followed by chemotherapy and surgery compared with long course chemoradiotherapy and surgery a 5 year follow up of the rapido trial
topic locally advanced rectal cancer
locoregional failure
locoregional recurrence
total neoadjuvant treatment
url https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=40&cateName=2024%E5%B9%B4%20%E7%AC%AC30%E5%8D%B7%20%E7%AC%AC1%E6%9C%9F
work_keys_str_mv AT liuxiaojun commentlocoregionalfailureduringandaftershortcourseradiotherapyfollowedbychemotherapyandsurgerycomparedwithlongcoursechemoradiotherapyandsurgerya5yearfollowupoftherapidotrial